Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Dendritic Cells Loaded With Exosomes Derived From Cancer Stem Cell-Enriched Spheroids As a Potential Immunotherapeutic Option Publisher Pubmed



Naseri M1, 2 ; Zoller M3 ; Hadjati J4 ; Ghods R1, 2 ; Ranaei Pirmardan E5 ; Kiani J1, 2 ; Eini L1, 6 ; Bozorgmehr M1 ; Madjd Z1, 2
Authors
Show Affiliations
Authors Affiliations
  1. 1. Oncopathology Research Center, Iran University of Medical Sciences (IUMS), Tehran, Iran
  2. 2. Department of Molecular Medicine, Faculty of Advanced Technologies in Medicine, Iran University of Medical Sciences (IUMS), Tehran, Iran
  3. 3. Section Pancreas Research, University Hospital of Surgery, Heidelberg, Germany
  4. 4. Department of Immunology, School of Medicine, Tehran University of Medical Sciences (TUMS), Tehran, Iran
  5. 5. Department of Radiology, Molecular Biomarkers Nano-imaging Laboratory, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, United States
  6. 6. Department of Basic Science, Faculty of Veterinary, Science and Research Branch of Islamic, Azad University, Tehran, Iran

Source: Journal of Cellular and Molecular Medicine Published:2021


Abstract

Cancer stem cells (CSCs) are responsible for therapeutic resistance and recurrence in colorectal cancer. Despite advances in immunotherapy, the inability to specifically eradicate CSCs has led to treatment failure. Hence, identification of appropriate antigen sources is a major challenge in designing dendritic cell (DC)-based therapeutic strategies against CSCs. Here, in an in vitro model using the HT-29 colon cancer cell line, we explored the efficacy of DCs loaded with exosomes derived from CSC-enriched colonospheres (CSCenr-EXOs) as an antigen source in activating CSC-specific T-cell responses. HT-29 lysate, HT-29-EXOs and CSCenr lysate were independently assessed as separate antigen sources. Having confirmed CSCs enrichment in spheroids, CSCenr-EXOs were purified and characterized, and their impact on DC maturation was investigated. Finally, the impact of the antigen-pulsed DCs on the proliferation rate and also spheroid destructive capacity of autologous T cells was assessed. CSCenr-EXOs similar to other antigen groups had no suppressive/negative impacts on phenotypic maturation of DCs as judged by the expression level of costimulatory molecules. Notably, similar to CSCenr lysate, CSCenr-EXOs significantly increased the IL-12/IL-10 ratio in supernatants of mature DCs. CSCenr-EXO-loaded DCs effectively promoted T-cell proliferation. Importantly, T cells stimulated with CSCenr-EXOs disrupted spheroids' structure. Thus, CSCenr-EXOs present a novel and promising antigen source that in combination with conventional tumour bulk-derived antigens should be further explored in pre-clinical immunotherapeutic settings for the efficacy in hampering recurrence and metastatic spread. © 2021 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd.
Other Related Docs
10. Exosomes and Micrornas in Biomedical Science, Synthesis Lectures on Biomedical Engineering (2022)
19. Tumor Antigens, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2019)
20. Circular Rnas (Circrnas) in Cancer Proliferation: Molecular Interactions and Possible Therapeutic Targets, Non-coding RNA Transcripts In Cancer Therapy: Pre-clinical And Clinical Implications (2023)
28. Tumor Antigens, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2018)
31. Cancer Immunotherapy: Diverse Approaches and Obstacles, Current Pharmaceutical Design (2022)
43. Nanoparticulate Systems for Dental Drug Delivery, Nanoengineered Biomaterials for Advanced Drug Delivery (2020)
44. Immunology of Cutaneous Tumors and Immunotherapy for Melanoma, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2015)
45. Role of Exosomes in the Treatment of Diseases, Synthesis Lectures on Biomedical Engineering (2022)
46. Tumor-Educated Platelets, Clinica Chimica Acta (2024)
49. Immunotherapy in Aml: A Brief Review on Emerging Strategies, Clinical and Translational Oncology (2021)